Search

Margalit T Mokyr

from Skokie, IL
Age ~79
Get Report
Also known as:
Margalit B Mokyr, Margalita B Mokyr, Margali T Mokyr, Margall Mokyr
Phone and address:
4540 Davis St, Skokie, IL 60076
(847) 679-8687
Related to:
Timothy R Thomas, 71Elizabeth Mokyr Horner, 43Naama Mokyr, 50Geoffrey A Horner, 44Elizabeth Mokyr, 36Joel Mokyr, 78
Connected to:
Anna J Mol, 51Barbara A Mol, 69Clifford D Mol, 62Cornelia R Mol, 72Edward Mol, 43Joy Mol, 98Marie Mol, 42Mark A Mol, 44Nancy E Mol, 93Teresa M Mol, 73

Margalit Mokyr Phones & Addresses

  • 4540 Davis St, Skokie, IL 60076 (847) 679-8687
  • 2243 Pike Rd, New Era, MI 49446 (231) 861-6837
  • 1738 Chicago Ave, Evanston, IL 60201 (847) 733-9640
  • 1738 Chicago Ave #405, Evanston, IL 60201 (847) 733-9640
  • San Francisco, CA

Publications

Wikipedia

Joel Mokyr

View page

Joel Mokyr (PhD Yale, 1974) is an American economic historian. Moykr was ... [ edit] Family. Mokyr is married to Margalit Mokyr and they have two daughters.

Us Patents

Animal Model For Testing Immunotherapies Of Spontaneous Metastatic Disease

View page
US Patent:
20010046502, Nov 29, 2001
Filed:
Feb 1, 2001
Appl. No.:
09/775537
Inventors:
Margalit Mokyr - Chicago IL, US
Assignee:
The Board of trustees of the University of Illinois
International Classification:
A61K049/00
A01K067/00
A61K039/00
US Classification:
424/277100, 424/009200, 800/010000
Abstract:
The present invention provides an animal model that can provide information on the effectiveness of postsurgical immunotherapies for recurrence of metastatic disease. In a specific embodiment, this tumor model used mice from which the primary 410.4 mammary carcinoma was surgically excised to assess the therapeutic potential of low-dose cyclophosphamide (CY) followed by vaccination with DNP-modified, -irradiated, autologous tumor cells admixed with BCG compared to mice receiving low-dose CY followed by vaccination with unmodified, -irradiated, autologous tumor cells admixed with BCG, or mice treated with PBS (control group). In this model, therapeutic benefits offered by DNP-modified, -irradiated, autologous tumor cell vaccine (preceded by low-dose CY) were abrogated completely upon depletion of CD8 T-cells, and was improved when the mice were pretreated with a single dose of DNP-modified, -irradiated, autologous tumor cells (without BCG) prior to the low-dose CY treatment, and then subjected to vaccination with DNP-modified, -irradiated, autologous tumor cells admixed with BCG.

Cryopreservation Of Haptenized Tumor Cells

View page
US Patent:
20050233301, Oct 20, 2005
Filed:
Dec 9, 2004
Appl. No.:
11/009192
Inventors:
David Berd - Wyncote PA, US
Lorne Erdile - Loudonville NY, US
Margalit Mokyr - Skokie IL, US
International Classification:
A01N001/02
US Classification:
435002000
Abstract:
A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to −80 C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.

Cryopreservation Of Haptenized Tumor Cells

View page
US Patent:
20070237795, Oct 11, 2007
Filed:
Jun 13, 2007
Appl. No.:
11/762409
Inventors:
David Berd - Wyncote PA, US
Lorne Erdile - Loudonville NY, US
Margalit Mokyr - Skokie IL, US
International Classification:
A01N 1/02
A61K 39/385
US Classification:
424277100, 435002000
Abstract:
A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to −80 C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.

Cryopreservation Of Haptenized Tumor Cells

View page
US Patent:
20140113371, Apr 24, 2014
Filed:
May 6, 2013
Appl. No.:
13/888024
Inventors:
David Berd - Wyncote PA, US
Lorne F. Erdile - Loudonville NY, US
Margalit B. Mokyr - Skokie IL, US
International Classification:
A01N 1/02
US Classification:
435374
Abstract:
A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to −80 C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.
Control profile
Margalit T Mokyr from Skokie, IL, age ~79 Get Report